The biotech paradigm. (biotechnology industry) (CE Roundtable) (Panel Discussion): An article from: Chief Executive (U.S.)
Book Details
PublisherChief Executive Publishing
ISBN / ASINB00092TAOQ
ISBN-13978B00092TAO3
AvailabilityAvailable for download now
MarketplaceUnited States 🇺🇸
Description
This digital document is an article from Chief Executive (U.S.), published by Chief Executive Publishing on October 1, 1993. The length of the article is 5255 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
From the supplier: The US biotechnology industry faces an uncertain future, with the unstable relationship with Wall Street, the impending imposition of ceiling prices on drug products and the need for additional capital for the entrance of new products in the offing. A panel discussion composed of CEOs of major pharmaceutical companies have dealt with issues concerning the prevailing business conditions. Some have decided to refocus plans to become fully established pharmaceutical companies and instead merge with larger enterprises while others have opted to re-structure their pricing policies and marketing strategies. Among the participants were Frederick Frank of Lehman Brothers, Kenneth I. Moch of Biocyte, George Ebright of Cytogen, Michael A. Romansky of McDermott, Will and Emery, Sandford D. Smith of Repligen, Michael Sayare of Immunogen, Robert Easton of The Wilerson Group, and William W. Crouse of Ortho Diagnostic Systems.
Citation Details
Title: The biotech paradigm. (biotechnology industry) (CE Roundtable) (Panel Discussion)
Publication:Chief Executive (U.S.) (Magazine/Journal)
Date: October 1, 1993
Publisher: Chief Executive Publishing
Issue: n89 Page: p54(11)
Article Type: Panel Discussion
Distributed by Thomson Gale
From the supplier: The US biotechnology industry faces an uncertain future, with the unstable relationship with Wall Street, the impending imposition of ceiling prices on drug products and the need for additional capital for the entrance of new products in the offing. A panel discussion composed of CEOs of major pharmaceutical companies have dealt with issues concerning the prevailing business conditions. Some have decided to refocus plans to become fully established pharmaceutical companies and instead merge with larger enterprises while others have opted to re-structure their pricing policies and marketing strategies. Among the participants were Frederick Frank of Lehman Brothers, Kenneth I. Moch of Biocyte, George Ebright of Cytogen, Michael A. Romansky of McDermott, Will and Emery, Sandford D. Smith of Repligen, Michael Sayare of Immunogen, Robert Easton of The Wilerson Group, and William W. Crouse of Ortho Diagnostic Systems.
Citation Details
Title: The biotech paradigm. (biotechnology industry) (CE Roundtable) (Panel Discussion)
Publication:Chief Executive (U.S.) (Magazine/Journal)
Date: October 1, 1993
Publisher: Chief Executive Publishing
Issue: n89 Page: p54(11)
Article Type: Panel Discussion
Distributed by Thomson Gale
